“It may be that, some ages hence... the restoration of grey hairs to juvenility and the renewing of the exhausted marrow may at length be elicited without a miracle”
Joseph Glanvill,
1661AD
Preventing transplant rejection
Endovascular cells play a key role in the early stages of pregnancy by improving blood flow to a developing placenta and preventing rejection of both the foetus and placenta by secretion of HLA-G, angiogenic and anti-inflammatory factors such as IL10.
Data shows that HLA-G has a similar function ex-utero and that HLA molecules play an important role in allowing an individual to recognise cells within the body as self or non-self. It is this recognition of cells that can result in an organ rejection occurring in transplant patients.
Axordia identified that the key characteristics of endovascular cells, namely the ability to:
- remodel localised blood supply; and
- prevent localised foetal rejection by inducing tolerogenesis.
could meet the key requirements of a patient when undergoing an organ transplantation, namely:
- improving vascularisation around a transplant to encourage quick healing; and
- convincing the body that the new cells are not foreign and stopping the bodies natural immune system from rejecting them
Clearly if Axordia’s endovascular cells platform technology could be developed into therapeutic applications for the transplantation market it would have considerable value.